SIGNANT HEALTH
THE EVIDENCE GENERATION COMPANY™

SmartSignals™ Solutions for Idiopathic Pulmonary Fibrosis

CLINICAL DEVELOPMENT SOLUTIONS TO IMPROVE IPF STUDY OUTCOMES

Among interstitial lung diseases, Idiopathic Pulmonary Fibrosis (IPF) remains an area with high mortality and extremely limited treatment options. Your IPF research program represents hope to millions of patients. That's why we tailored Signant Health's SmartSignals™ solutions to address research challenges so you can deliver new and better treatment options.

CONDUCT 6MWT CONSISTENTLY

Variability and inconsistency in the administration of the six-minute walk test results in unreliable assessment and endpoint data. Signant's Rater Training solution and video production services to ensure raters conduct the 6MWT correctly and consistently across sites and studies.

COLLECT ACCURATE COA DATA

If your protocol requires L-IPF, Cough VAS, PGI-C/S, or other site-based questionnaires, leverage our eCOA platform to collect more complete and accurate data. In addition, this method reduces burden of use for both patients and sites.

IMPROVE OPERATIONAL EFFICIENCY

Conducting studies in many countries and across many sites introduces logistical challenges that can be the source of errors or delays. Study teams trust our RTSM system to not only launch studies faster but to handle complex cohorting, study supply forecasting, and data transfers with efficiency and accuracy.

REDUCE PARTICIPANT BURDENS

IPF makes everyday tasks difficult for patients. Simplify the clinical trial participation experience by providing tools like eConsent and Telemedicine that reduce the need for complicated form completions or site visits. As an added bonus, sites benefit by maintaining up-to-date ICFs and consulting with patients remotely.

GAIN EXPERT GUIDANCE

From consulting on outcome measure selection to scale management and rater training services, Signant's in-house experts will help you navigate common IPF challenges from study launch to closeout. Talk through your protocol with experienced clinical science and medicine experts.

DIGITALIZE THE PROCESS

Any of our clinical research technology solutions and services can be used individually, but when you combine them, your study will be optimized from end-to-end to deliver accurate endpoint data.

At Signant, our focus is helping you develop and deliver treatments or therapies faster in order to improve the quality of life for IPF patients everywhere.

SIGNANT'S IPF CLINICAL TRIAL EXPERIENCE

Phases

I II III



1 Language

467 Sites

16 Countries

875 Patients

8 Protocols

SMARTSIGNALS SOLUTIONS

The SmartSignals solutions can be used individually or integrated together for a seamless, end-to-end digital experience.

eCOA

Scientific Advisory

Telemedicine

eConsent

RTSM

DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



MEET THE EXPERTS